XML 78 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
May 08, 2023
Mar. 31, 2020
Mar. 31, 2020
Dec. 31, 2023
Dec. 31, 2022
Collaboration And License Agreements [Line Items]          
Collaboration and license revenue       $ 21,049 $ 13,535
Incurred costs       114,507 80,171
Deferred revenue, current portion       10,137 $ 3,874
Long-term deferred revenue       $ 5,622  
Maximum | Novartis Agreement          
Collaboration And License Agreements [Line Items]          
Ownership Interest       10.00% 10.00%
Minimum | Novartis Agreement          
Collaboration And License Agreements [Line Items]          
Ownership Interest   10.00% 10.00%    
Amgen Inc. | Amgen Agreement          
Collaboration And License Agreements [Line Items]          
License agreement date May 08, 2023        
Upfront payment receivable $ 30,000        
Potential milestone payment $ 500,000        
Expects research term 3 years        
Collaboration and license revenue       $ 14,200  
Deferred revenue       15,800  
Long-term deferred revenue       5,600  
Novartis          
Collaboration And License Agreements [Line Items]          
License agreement date     Mar. 31, 2020    
Upfront payment receivable   $ 20,000 $ 20,000    
Collaboration and license revenue       5,800 $ 13,500
Reimbursement cost       $ 1,900 $ 4,500
Novartis | Research Funding          
Collaboration And License Agreements [Line Items]          
Upfront payment received     $ 10,000